User: Guest

HIV DRUGS

Global Market Trajectory & Analytics

MCP-6176

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8299

Interactions with Platform & by Email *

INTERACTIONS

1162

Unique # Participated *

PARTICIPANTS

249

Responses Validated *

VALIDATIONS

112

* Login to view program details and full enterprise executive list.

  •  DATE

    JULY 2020

  •  TABLES

    123

  •  PAGES

    205

  •  EDITION

    16

  •  PRICE

    USD $5450

COVID-19 IMPACT SURVEY
Amid the COVID-19 crisis, the global market for HIV Drugs estimated at US$22.8 Billion in the year 2020, is projected to reach a revised size of US$26.8 Billion by 2027, growing at a CAGR of 2.3% over the analysis period 2020-2027.Multi-Class Combination Drugs, one of the segments analyzed in the report, is projected to grow at a 2.7% CAGR to reach US$9.8 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Nucleoside Reverse Transcriptase Inhibitors (NRTIs) segment is readjusted to a revised 2.7% CAGR for the next 7-year period. This segment currently accounts for a 23.9% share of the global HIV Drugs market.
The HIV Drugs market in the U.S. is estimated at US$6.2 Billion in the year 2020. The country currently accounts for a 27.05% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$5.3 Billion in the year 2027 trailing a CAGR of 4.4% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.5% and 1.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1% CAGR while Rest of European market (as defined in the study) will reach US$5.3 Billion by the year 2027.
In the global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) segment, USA, Canada, Japan, China and Europe will drive the 1.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.7 Billion in the year 2020 will reach a projected size of US$2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.6 Billion by the year 2027, while Latin America will expand at a 2.9% CAGR through the analysis period. We bring years of research experience to this 16th edition of our report. The 205-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others, AbbVie, Inc.; AstraZeneca PLC; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Cipla Ltd.; Daiichi Sankyo Co., Ltd.; Emcure Pharmaceuticals Pvt., Ltd.; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Hetero Drugs Ltd.; Johnson & Johnson; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd.; ViiV Healthcare
» Medication Class [Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors, and HIV Integrase Stand Transfer Inhibitors]
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

  • A: 
    ACTIVE CLIENT
  • B: 
    INACTIVE CLIENT
  • C: 
    ACTIVE PANELIST
  • D: 
    INACTIVE PANELIST
  • E: 
    OPT-INS
  
REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com